RNA Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

Harga

$12.90

Kapitalisasi Pasar

$1.95B

P/E (TTM)

-2.6

EPS (TTM)

$-4.97

Pendapatan (TTM)

$19M

Imbal Hasil Dividen

—

ROE

-47.5%

D/E Utang/Ekuitas

—

Rentang 52M

$11 – $73

RNA Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

Pendapatan & Laba Bersih $19M

2018-12-31 → 2025-12-31

EPS $-4.97

2020-12-31 → 2025-12-31

Arus Kas Bebas $-664M

2020-12-31 → 2025-12-31

Margin -3650.4%

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Metrik

Tren 5 Tahun

RNA

Median Rekan

P/E (TTM)

-2.6

—

P/S (TTM)

104.0

9.5

P/B

1.2

1.1

Price / FCF (Harga / FCF)

-2.9

—

Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC

Metrik

Tren 5 Tahun

RNA

Median Rekan

Operating Margin (Margin Operasi)

-3977.3%

—

Net Profit Margin (Margin Laba Bersih)

-3650.4%

-348.2%

ROA

-38.9%

-40.7%

ROE

-47.5%

-49.8%

ROIC

-44.2%

—

Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca

Metrik

Tren 5 Tahun

RNA

Median Rekan

Current Ratio (Rasio Lancar)

9.2

12.1

Quick Ratio (Rasio Cepat)

2.0

—

Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T

Metrik

Tren 5 Tahun

RNA

Median Rekan

Revenue YoY (Pendapatan YoY)

72.1%

—

Revenue CAGR 3Y (CAGR Pendapatan 3T)

26.7%

—

Revenue CAGR 5Y (CAGR Pendapatan 5T)

22.5%

—

Metrik Per Saham EPS, nilai buku per saham, arus kas per saham, dividen per saham

Metrik

Tren 5 Tahun

RNA

Median Rekan

EPS (Diluted)

$-4.97

—

Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang

Metrik

Tren 5 Tahun

RNA

Median Rekan

RNA Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

BELI 7 analis

Beli Kuat 2 28,6%
Beli 4 57,1%
Tahan 1 14,3%
Jual 0 0,0%
Jual Kuat 0 0,0%

Target Harga 12 Bulan

4 analis · 2026-08-19

Rendah $25.00

Tinggi $25.00

Target median $25.00 +93,8%

Target rata-rata $25.00 +93,8%

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

Kejutan Rata-rata

0.09%

Periode	EPS Aktual	EPS Estimasi	Kejutan
31 Maret 2026	$-0.97	$-1.06	0.09%

Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor

Ticker	Kapitalisasi Pasar	P/E	Pendapatan YoY	Margin Bersih	ROE	Margin Kotor
RNA	$10.91B	-14.5	72.1%	-3650.4%	-47.5%	—
EBS	$644M	13.3	-28.8%	7.1%	9.9%	—
ARCT	$174M	-2.6	-46.1%	-80.2%	-29.6%	—
NBP	—	—	—	—	—	—
IMUX	—	-0.9	—	—	—	—
ORGO	$658M	34.5	17.0%	6.6%	13.9%	—
NERV	$174M	-0.1	—	—	339.5%	—
IVVD	$697M	-8.2	110.5%	-98.2%	-36.9%	—
TNXP	$200M	-1.1	29.8%	-946.2%	-60.0%	—
WHWK	$114M	-7.3	-72.5%	-288.3%	-13.4%	—
PEPG	$448M	-3.1	—	—	-82.0%	—

Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas

Laporan Laba Rugi 15

Data Laporan Laba Rugi Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2021	2020	2019
Revenue	$19M	$11M	$10M	$9M	$9M	$7M	$2M
R&D Expense	$559M	$304M	$191M	$150M	$101M	$38M	$15M
SG&A Expense	$206M	$86M	$54M	$38M	$26M	$13M	$5M
Operating Expenses	$765M	$390M	$245M	$188M	$127M	$51M	$20M
Operating Income	$-746M	$-379M	$-236M	$-179M	$-118M	$-44M	$-17M
Interest Expense	·	·	·	$0	$0	$209.0K	$7M
Other Non-op	$-2M	$-248.0K	$-594.0K	$-57.0K	$-62.0K	$-75.0K	$0
Pretax Income	$-685M	$-322M	$-212M	·	·	·	·
Income Tax	$0	$0	$0	$0	$0	$0	$0
Net Income	$-685M	$-322M	$-212M	$-174M	$-118M	$-44M	$-25M
EPS (Basic)	$-4.97	$-2.89	$-2.91	$-3.34	$-2.85	$-2.05	·
EPS (Diluted)	$-4.97	$-2.89	$-2.91	$-3.34	$-2.85	$-2.05	·
Shares (Basic)	137,710,000	111,582,000	73,012,000	52,162,000	41,428,000	21,663,000	·
Shares (Diluted)	137,710,000	111,582,000	73,012,000	52,162,000	41,428,000	21,663,000	·
EBITDA	$-746M	$-379M	$-236M	$-179M	$-118M	$-44M	·

Neraca 24

Data Neraca Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2021	2020	2019
Cash & Equivalents	$383M	$220M	$185M	$340M	$320M	$321M	$95M
Short-term Investments	·	·	·	·	$85M	$7M	·
Receivables	·	$0	$1M	$2M	·	·	·
Prepaid Expense	$102M	$41M	$16M	$12M	$6M	·	·
Other Current Assets	$53M	$19M	·	$2M	·	·	·
Current Assets	$1.80B	$1.54B	$611M	$623M	$411M	$332M	$96M
PP&E (Net)	$23M	$13M	$8M	$6M	$5M	$1M	$631.0K
PP&E (Gross)	$35M	$21M	$14M	$9M	$7M	$3M	$2M
Accum. Depreciation	$12M	$8M	$5M	$3M	$2M	$2M	$2M
Other Non-current Assets	$82M	$521.0K	$301.0K	$598.0K	$599.0K	$47.0K	$600.0K
Total Assets	$1.96B	$1.56B	$629M	$639M	$428M	$334M	$97M
Accounts Payable	$12M	$8M	$9M	$5M	$3M	$8M	$2M
Current Liabilities	$195M	$98M	$81M	$52M	$30M	$15M	$10M
Capital Leases	$45M	$3M	$6M	$8M	$10M	$938.0K	$393.0K
Other Non-current Liabilities	·	·	·	·	·	·	$45.0K
Total Liabilities	$269M	$139M	$128M	$61M	$46M	$28M	$28M
Long-term Debt	·	·	·	·	·	·	$5M
Common Stock	$15.0K	$12.0K	$8.0K	$7.0K	$5.0K	$4.0K	$0
Paid-in Capital	·	·	·	$939M	$566M	$373M	$-43M
Retained Earnings	$-1.58B	$-893M	$-571M	$-359M	$-185M	$-67M	$-22M
AOCI	$3M	$3M	$125.0K	$-3M	$-187.0K	$-5.0K	·
Stockholders' Equity	$1.69B	$1.42B	$501M	$578M	$381M	$306M	$-65M
Liabilities + Equity	$1.96B	$1.56B	$629M	$639M	$428M	$334M	$97M
Shares Outstanding	151,205,000	119,893,000	79,275,000	69,768,000	47,754,000	37,569,000	2,989,000

Arus Kas 10

Data Arus Kas Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2021	2020	2019
Stock-based Comp	$98M	$51M	$38M	$27M	$17M	$4M	$406.0K
Operating Cash Flow	$-650M	$-301M	$-119M	$-136M	$-95M	$-37M	$2M
CapEx	$13M	$7M	$4M	$3M	$4M	$1M	$235.0K
Investing Cash Flow	$-38M	$-854M	$-130M	$-190M	$-83M	$-8M	$-235.0K
Net Debt Issued	·	·	·	$0	$0	$-5M	·
Stock Issued	$837M	$762M	$61M	$345M	$175M	$274M	·
Net Stock Activity	$837M	$762M	$61M	$345M	$20M	·	·
Financing Cash Flow	$851M	$1.19B	$94M	$346M	$176M	$272M	$89M
Net Change in Cash	$163M	$37M	$-155M	$20M	$-1M	$227M	$91M
Free Cash Flow	$-664M	$-308M	$-123M	$-139M	$-99M	$-38M	·

Profitabilitas 7

Data Profitabilitas Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2021	2020	2019
Operating Margin	-3977.3%	-3477.4%	-2464.4%	-1939.6%	-1265.8%	-652.4%	·
Net Margin	-3650.4%	-2957.7%	-2219.9%	-1886.3%	-1265.4%	-653.5%	·
Pretax Margin	-3650.4%	·	·	·	·	·	·
EBITDA Margin	-3977.3%	-3477.4%	-2464.4%	-1939.6%	-1265.8%	-652.4%	·
ROA	-38.9%	-29.4%	-33.5%	-32.6%	-31.0%	-20.6%	·
ROE	-47.5%	-22.0%	-41.7%	-36.4%	-30.4%	-14.2%	·
ROIC	-44.2%	·	·	·	·	·	·

Likuiditas & Solvabilitas 3

Data Likuiditas & Solvabilitas Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2021	2020	2019
Current Ratio	9.2	15.7	7.6	12.0	13.9	22.7	·
Quick Ratio	2.0	2.2	2.3	6.6	13.7	22.5	·
Interest Coverage	·	·	·	·	·	-211.9	·

Efisiensi 2

Data Efisiensi Tahunan untuk RNA
Metrik	Tren	2025	2024	2023	2022	2021	2020	2019
Asset Turnover		0.0	0.0	0.0	0.0	0.0	0.0	·
Receivables Turnover		·	19.7	5.5	·	·	·	·

Per Saham 5

Data Per Saham Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2021	2020	2019
Book Value / Share	$11.17	$11.89	$6.32	$8.29	$7.99	$8.15	·
Revenue / Share	$0.14	$0.10	$0.13	$0.18	·	·	·
Cash Flow / Share	$-4.72	$-2.70	$-1.63	$-2.61	·	·	·
Cash / Share	$2.53	$1.83	$2.33	$4.88	$6.71	$8.56	·
EPS (TTM)	$-4.97	$-2.89	$-2.91	$-3.34	$-2.85	$-2.05	·

Tingkat Pertumbuhan 3

Data Tingkat Pertumbuhan Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2021	2020	2019
Revenue YoY	72.1%	14.0%	3.6%	-1.1%	37.4%	·	·
Revenue CAGR 3Y	26.7%	5.3%	12.1%	·	·	·	·
Revenue CAGR 5Y	22.5%	·	·	·	·	·	·

Valuasi (TTM) 10

Data Valuasi (TTM) Tahunan untuk RNA
Metrik	2025	2024	2023	2022	2021	2020	2019
Revenue TTM	$19M	$11M	$10M	$9M	$9M	$7M	·
Net Income TTM	$-685M	$-322M	$-212M	$-174M	$-118M	$-44M	·
Market Cap	$10.91B	$3.49B	$717M	$1.55B	$1.14B	$959M	·
P/E	-14.5	-10.1	-3.1	-6.6	-8.3	-12.4	·
P/S	581.5	319.9	75.0	167.8	121.7	141.3	·
P/B	6.5	2.4	1.4	2.7	3.0	3.1	·
P / Tangible Book	6.5	2.4	1.4	2.7	3.0	3.1	·
P / Cash Flow	-16.8	-11.6	-6.0	-11.4	-12.0	-25.8	·
P / FCF	-16.4	-11.3	-5.8	-11.1	-11.5	-25.1	·
Earnings Yield	-6.9%	-9.9%	-32.1%	-15.0%	-12.0%	-8.0%	·

Laporan Laba Rugi 12

Data Triwulanan Laporan Laba Rugi untuk RNA
Metrik	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Revenue	$860.0K	$12M	$4M	$2M	$3M	$2M	$2M	$4M	$2M	$3M	$2M	$2M	$3M	$2M	$2M	$2M
R&D Expense	$167M	$155M	$138M	$99M	$96M	$77M	$64M	$67M	$53M	$48M	$43M	$48M	$46M	$37M	$40M	$28M
SG&A Expense	$89M	$46M	$37M	$34M	$28M	$23M	$21M	$14M	$16M	$14M	$12M	$12M	$10M	$10M	$9M	$9M
Operating Expenses	$255M	$201M	$175M	$133M	$124M	$100M	$85M	$81M	$69M	$61M	$55M	$60M	$56M	$47M	$48M	$36M
Operating Income	$-254M	$-189M	$-171M	$-132M	$-121M	$-98M	$-83M	$-77M	$-67M	$-59M	$-53M	$-58M	$-53M	$-45M	$-46M	$-34M
Other Non-op	$-477.0K	$-380.0K	$-651.0K	$-435.0K	$201.0K	$-232.0K	$-116.0K	$-101.0K	$-105.0K	$-13.0K	$-162.0K	$-314.0K	$-18.0K	$-12.0K	$-2.0K	$-25.0K
Net Income	$-237M	$-174M	$-157M	$-116M	$-102M	$-80M	$-71M	$-69M	$-60M	$-52M	$-47M	$-52M	$-50M	$-44M	$-46M	$-34M
EPS (Basic)	$-1.59	$-1.27	$-1.21	$-0.90	$-0.80	$-0.65	$-0.65	$-0.79	$-0.80	$-0.71	$-0.66	$-0.74	$-0.89	$-0.82	$-0.92	$-0.71
EPS (Diluted)	$-1.59	$-1.27	$-1.21	$-0.90	$-0.80	$-0.65	$-0.65	$-0.79	$-0.80	$-0.71	$-0.66	$-0.74	$-0.89	$-0.82	$-0.92	$-0.71
Shares (Basic)	-259,039,000	137,895,000	129,622,000	129,232,000	-205,933,000	123,375,000	106,928,000	87,212,000	-142,908,000	74,097,000	71,390,000	70,433,000	-99,080,000	53,069,000	49,927,000	48,246,000
Shares (Diluted)	-259,039,000	137,895,000	129,622,000	129,232,000	-205,933,000	123,375,000	106,928,000	87,212,000	-142,908,000	74,097,000	71,390,000	70,433,000	-99,080,000	53,069,000	49,927,000	48,246,000
EBITDA	·	$-189M	$-171M	$-132M	·	$-98M	$-83M	$-77M	·	$-59M	$-53M	$-58M	·	$-45M	·	$-34M

Neraca 21

Data Triwulanan Neraca untuk RNA
Metrik	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Cash & Equivalents	$383M	$350M	$244M	$254M	$220M	$370M	$576M	$471M	·	$86M	$154M	$119M	·	$144M	$125M	$139M
Short-term Investments	·	·	·	·	·	·	·	·	·	·	·	·	·	$262M	$273M	$258M
Receivables	·	·	·	·	·	$0	$0	$2M	·	·	$1M	·	·	·	·	·
Prepaid Expense	$102M	$90M	$67M	$55M	$41M	$33M	$30M	$19M	·	·	$11M	·	·	·	·	·
Other Current Assets	$53M	$60M	$43M	·	$19M	·	·	·	·	·	$6M	·	·	·	·	·
Current Assets	$1.80B	$1.97B	$1.25B	$1.43B	$1.54B	$1.62B	$1.33B	$934M	·	$555M	$595M	$597M	·	$414M	$404M	$405M
PP&E (Net)	$23M	$22M	$21M	$16M	$13M	$9M	$8M	$9M	·	$8M	$8M	$8M	·	$6M	$6M	$5M
PP&E (Gross)	$35M	$32M	$30M	$24M	$21M	$17M	$15M	$15M	·	$13M	$12M	$11M	·	$9M	$9M	$7M
Accum. Depreciation	$12M	$10M	$10M	$9M	$8M	$7M	$7M	$6M	·	$5M	$4M	$4M	·	$3M	$2M	$2M
Other Non-current Assets	$82M	$91M	$91M	$739.0K	$521.0K	$318.0K	$364.0K	$425.0K	·	$344.0K	$424.0K	$474.0K	·	$523.0K	$415.0K	$548.0K
Total Assets	$1.96B	$2.13B	$1.37B	$1.46B	$1.56B	$1.64B	$1.35B	$951M	·	$573M	$611M	$614M	·	$431M	$421M	$421M
Accounts Payable	$12M	$10M	$4M	$7M	$8M	$8M	$9M	$2M	·	$6M	$6M	$4M	·	$26M	$21M	$19M
Current Liabilities	$195M	$170M	$135M	$85M	$98M	$91M	$84M	$75M	·	$49M	$45M	$48M	·	$43M	$34M	$31M
Capital Leases	$45M	$46M	$1M	$2M	$3M	$4M	$5M	$5M	·	$7M	$6M	$7M	·	$8M	$9M	$9M
Total Liabilities	$269M	$248M	$176M	$130M	$139M	$137M	$126M	$121M	·	$56M	$52M	$55M	·	$54M	$46M	$45M
Common Stock	$15.0K	$15.0K	$12.0K	$12.0K	$12.0K	$12.0K	$11.0K	$10.0K	·	$7.0K	$7.0K	$7.0K	·	$5.0K	$5.0K	$5.0K
Retained Earnings	$-1.58B	$-1.34B	$-1.17B	$-1.01B	$-893M	$-791M	$-710M	$-640M	·	$-510M	$-458M	$-411M	·	$-308M	$-264M	$-219M
AOCI	$3M	$2M	$2M	$3M	$3M	$7M	$-453.0K	$-464.0K	·	$-2M	$-3M	$-2M	·	$-3M	$-3M	$-2M
Stockholders' Equity	$1.69B	$1.89B	$1.19B	$1.33B	$1.42B	$1.50B	$1.22B	$831M	$501M	$517M	$559M	$559M	$578M	$377M	$374M	$376M
Liabilities + Equity	$1.96B	$2.13B	$1.37B	$1.46B	$1.56B	$1.64B	$1.35B	$951M	·	$573M	$611M	$614M	·	$431M	$421M	$421M
Shares Outstanding	151,205,000	146,771,000	120,778,000	120,512,000	119,893,000	118,900,000	109,266,000	95,594,000	79,275,000	74,101,000	74,070,000	70,813,000	69,768,000	54,446,000	52,081,000	49,281,000

Arus Kas 9

Data Triwulanan Arus Kas untuk RNA
Metrik	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Stock-based Comp	$43M	$19M	$18M	$18M	$14M	$14M	$13M	$10M	$10M	$10M	$9M	$9M	$7M	$7M	$7M	$6M
Operating Cash Flow	$-170M	$-156M	$-200M	$-125M	$-100M	$-66M	$-65M	$-70M	$17M	$-37M	$-50M	$-49M	$-39M	$-32M	$-36M	$-30M
CapEx	$6M	$712.0K	$3M	$4M	$4M	$2M	$531.0K	$915.0K	$863.0K	$923.0K	$622.0K	$2M	$850.0K	$-107.0K	$1M	$758.0K
Investing Cash Flow	$207M	$-588M	$185M	$157M	$-64M	$-482M	$-275M	$-33M	$51M	$-31M	$46M	$-196M	$-8M	$11M	$-18M	$-175M
Stock Issued	$-538.0K	$837M	$0	$0	$-500.0K	$324M	$433M	$6M	$0	$0	$38M	$22M	$243M	$39M	$38M	$24M
Net Stock Activity	·	·	·	$0	·	·	·	$6M	·	·	·	$22M	·	·	·	$24M
Financing Cash Flow	$-5M	$850M	$4M	$2M	$14M	$342M	$447M	$389M	$32M	$40.0K	$39M	$23M	$244M	$40M	$39M	$24M
Net Change in Cash	$32M	$106M	$-10M	$34M	$-150M	$-206M	$107M	$286M	$99M	$-68M	$35M	$-222M	$197M	$19M	$-14M	$-181M
Free Cash Flow	·	·	·	$-129M	·	·	·	$-71M	·	·	·	$-51M	·	·	·	$-30M

Profitabilitas 5

Data Triwulanan Profitabilitas untuk RNA
Metrik	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Operating Margin	·	-1513.5%	-4448.7%	-8360.9%	·	-4200.9%	-4040.4%	-2178.6%	·	-2080.4%	-2272.6%	-2579.3%	·	-1810.2%	·	-1919.8%
Net Margin	·	-1398.3%	-4089.3%	-7360.0%	·	-3441.7%	-3461.8%	-1943.4%	·	-1858.0%	-2030.4%	-2346.3%	·	-1756.6%	·	-1907.2%
EBITDA Margin	·	-1513.5%	-4448.7%	-8360.9%	·	-4200.9%	-4040.4%	-2178.6%	·	-2080.4%	-2272.6%	-2579.3%	·	-1810.2%	·	-1919.8%
ROA	·	-9.2%	-11.6%	-9.6%	·	-7.3%	-7.2%	-8.8%	·	-10.4%	-9.1%	-10.1%	·	-10.2%	·	-9.3%
ROE	·	-10.3%	-13.0%	-10.7%	·	-8.0%	-8.0%	-9.9%	·	-11.7%	-10.1%	-11.2%	·	-11.3%	·	-10.3%

Likuiditas & Solvabilitas 2

Data Triwulanan Likuiditas & Solvabilitas untuk RNA
Metrik	Tren	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Current Ratio		·	11.6	9.3	16.9	·	17.8	15.8	12.5	·	11.4	13.1	12.4	·	9.7	·	13.1
Quick Ratio		·	2.1	1.8	3.0	·	4.1	6.8	6.3	·	1.8	3.4	2.5	·	9.5	·	12.8

Efisiensi 2

Data Triwulanan Efisiensi untuk RNA
Metrik	Tren	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Asset Turnover		·	0.0	0.0	0.0	·	0.0	0.0	0.0	·	0.0	0.0	0.0	·	0.0	·	0.0
Receivables Turnover		·	·	·	·	·	·	3.5	4.5	·	·	3.9	·	·	·	·	·

Per Saham 5

Data Triwulanan Per Saham untuk RNA
Metrik	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Book Value / Share	·	$12.85	$9.87	$11.03	·	$12.64	$11.17	$8.69	·	$6.98	$7.55	$7.89	·	$6.92	·	$7.62
Revenue / Share	·	$0.09	$0.03	$0.01	·	$0.02	$0.02	$0.04	·	$0.04	$0.03	$0.03	·	$0.05	·	·
Cash Flow / Share	·	·	·	$-0.97	·	·	·	$-0.81	·	·	·	$-0.70	·	·	·	·
Cash / Share	·	$2.39	$2.02	$2.11	·	$3.11	$5.27	$4.93	·	$1.16	$2.08	$1.68	·	$2.64	·	$2.83
EPS (TTM)	·	$-4.03	$-3.41	$-2.99	·	$-2.80	$-2.81	$-2.90	·	$-2.93	$-3.14	$-3.19	·	$-3.13	·	·

Valuasi (TTM) 10

Data Triwulanan Valuasi (TTM) untuk RNA
Metrik	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022
Revenue TTM	·	$20M	$10M	$9M	·	$11M	$11M	$11M	·	$10M	$9M	$9M	·	$9M	·	$9M
Net Income TTM	·	$-528M	$-424M	$-336M	·	$-272M	$-239M	$-221M	·	$-195M	$-189M	$-176M	·	$-153M	·	$-114M
Market Cap	·	$6.39B	$3.43B	$3.56B	·	$5.46B	$4.46B	$2.44B	·	$473M	$821M	$1.09B	·	$889M	·	$910M
P/E	·	-10.8	-8.3	-9.9	·	-16.4	-14.5	-8.8	·	-2.2	-3.5	-4.8	·	-5.2	·	·
P/S	·	316.1	350.0	374.6	·	508.4	416.3	223.6	·	48.0	89.2	125.1	·	103.2	·	98.2
P/B	·	3.4	2.9	2.7	·	3.6	3.7	2.9	·	0.9	1.5	1.9	·	2.4	·	2.4
P / Tangible Book	·	3.4	2.9	2.7	·	3.6	3.7	2.9	·	0.9	1.5	1.9	·	2.4	·	2.4
P / Cash Flow	·	·	·	-28.5	·	·	·	-34.7	·	·	·	-22.2	·	·	·	-30.8
P / FCF	·	·	·	-27.7	·	·	·	-34.2	·	·	·	-21.4	·	·	·	-30.0
Earnings Yield	·	-9.2%	-12.0%	-10.1%	·	-6.1%	-6.9%	-11.4%	·	-45.9%	-28.3%	-20.8%	·	-19.2%	·	·

Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir

Laporan Laba Rugi

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Pendapatan	$19M	$11M	$10M	$9M	$9M
Margin Operasi %	-3977.3%	-3477.4%	-2464.4%	-1939.6%	-1265.8%
Laba Bersih	$-685M	$-322M	$-212M	$-174M	$-118M
EPS Dilusian	$-4.97	$-2.89	$-2.91	$-3.34	$-2.85

Neraca

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Rasio Lancar	9.2	15.7	7.6	12.0	13.9
Rasio Cepat	2.0	2.2	2.3	6.6	13.7

Arus Kas

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Arus Kas Bebas	$-664M	$-308M	$-123M	$-139M	$-99M

Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini

CureVac menuntut Moderna atas pelanggaran paten vaksin COVID-19 Yahoo Finance · 3 bulan, 3 minggu lalu

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap

📊

Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.

Pilihan Anda disimpan dan mengikuti Anda di semua ticker.

Pemilik institusional (13F) 20 pengaju · $102.7M total · Per tanggal 30 Juni 2026

Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.

Aktivitas institusional — Q2 2026 vs kuartal sebelumnya

Posisi baru	Posisi yang keluar	Meningkat	Menurun	Perubahan bersih saham
0 (0 vs Kuartal sebelumnya)	1 (-322 vs Kuartal sebelumnya)	0 (0 vs Kuartal sebelumnya)	1 (0 vs Kuartal sebelumnya)	-8K

Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.

Institusi	Nilai	Saham	% dari 13F yang dilacak	Tipe
KRYGER CAPITAL Ltd	$75.398.932	1.045.320	73,42%	Saham
VANGUARD GROUP INC	$6.863.530	95.155	6,68%	Saham
EFG Asset Management (North America) Corp.	$6.499.913	149.149	6,33%	Saham
AXA Investment Managers S.A.	$4.429.239	101.658	4,31%	Saham
ANGELO GORDON & CO., L.P.	$3.245.850	45.000	3,16%	Saham
Toroso Investments, LLC	$2.628.417	36.440	2,56%	Saham
WOLVERINE TRADING, LLC	$1.023.120	24.000	1,00%	Opsi beli
Orion Portfolio Solutions, LLC	$675.595	22.886	0,66%	Saham
CIBC WORLD MARKETS CORP	$552.372	7.658	0,54%	Saham
WOLVERINE TRADING, LLC	$456.141	10.700	0,44%	Opsi jual
Eisler Capital Management Ltd.	$322.088	7.600	0,31%	Opsi beli
WOLVERINE TRADING, LLC	$285.493	6.697	0,28%	Saham
Nuveen Asset Management, LLC	$167.268	5.752	0,16%	Saham
AlphaQuest LLC	$104.589	1.450	0,10%	Saham
OLIVER LAGORE VANVALIN INVESTMENT GROUP	$19.572	663	0,02%	Saham
Lindbrook Capital, LLC	$16.708	566	0,02%	Saham
COMERICA BANK	$10.956	152	0,01%	Saham
Byrne Asset Management LLC	$1.372	102	0,00%	Saham
FTB Advisors, Inc.	$511	18	0,00%	Saham
Hemington Wealth Management	$0	7	0,00%	Saham

Orang dalam perusahaan 20 orang dalam · 11 pejabat · 9 direktur

Orang Dalam	Peran	Aktivitas terakhir	Saham dimiliki	Bersih 12m
Sarah Boyce	President and CEO	27 Feb. 2026 D	0	$0
Michael F Maclean	Chief Financial Officer	27 Feb. 2026 D	0	$0
Joseph Baroldi	Chief Operating Officer	2 Feb. 2021 A	—	$0
Charles Calderaro III	Chief Technical Officer	27 Feb. 2026 D	0	$0
Kathleen P. Gallagher	Chief Program Officer	27 Feb. 2026 D	0	$0
Teresa Mccarthy	Chief Human Resources Officer	27 Feb. 2026 D	0	$0
Michael W. Flanagan	Chief Scientific Officer	27 Feb. 2026 D	0	$0
Steven George Hughes	Chief Medical Officer	27 Feb. 2026 D	0	$0
Eric Mosbrooker	Chief Commercial Officer	27 Feb. 2026 D	0	$0
John B Moriarty	Chief Legal Officer	27 Feb. 2026 D	0	$0
Jae B. Kim	Chief Medical Officer	2 Feb. 2021 A	—	$0
Simona Skerjanec	Direktur	27 Feb. 2026 D	0	$0
Jean Jinsun Kim	Direktur	27 Feb. 2026 D	0	$0
Tamar Thompson	Direktur	27 Feb. 2026 D	0	$0
Noreen Henig	Direktur	27 Feb. 2026 D	0	$0
Troy Edward Wilson	Direktur	27 Feb. 2026 D	0	$0
Edward M. Kaye MD	Direktur	27 Feb. 2026 D	0	$0
Carsten Boess	Direktur	27 Feb. 2026 D	0	$0
LEVIN ARTHUR A	Direktur	27 Feb. 2026 D	0	$0
Roderick Wong, M.D.	—	16 Juni 2021 A	—	$0

Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka

Aktivis & pemilik 5%+ 1 saham

Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.

Pengaju	Diajukan	Kepemilikan	Status	Tujuan	Pengajuan
RTW Investments, LP, Roderick Wong ×6 pengajuan	29 Okt. 2025	3,10%	Amandemen	—	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Kepemilikan ETF Dimiliki oleh 15 ETF

Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.

Dana	Bobot	Unit	Per tanggal	Sumber
IWC · iShares Trust	0,04%	48.184 SH	8 Agu 2026	Harian
OMFS · Invesco Exchange-Traded Self-Indexe…	0,02%	4.415 SH	8 Agu 2026	Harian
VTWO · VANGUARD SCOTTSDALE FUNDS	0,01%	82.327 SH	8 Agu 2026	Harian
VTWG · VANGUARD SCOTTSDALE FUNDS	0,01%	10.724 SH	8 Agu 2026	Harian
IWO · iShares Trust	0,01%	85.960 SH	8 Agu 2026	Harian
IWM · iShares Trust	0,01%	369.738 SH	8 Agu 2026	Harian
IWN · iShares Trust	0,00%	40.687 SH	8 Agu 2026	Harian
PRFZ · Invesco Exchange-Traded Fund Trust	0,00%	2.952 SH	8 Agu 2026	Harian
IWV · iShares Trust	0,00%	3.267 SH	8 Agu 2026	Harian
VXF · VANGUARD INDEX FUNDS	0,00%	188.626 SH	8 Agu 2026	Harian
VTI · VANGUARD INDEX FUNDS	0,00%	518.416 SH	8 Agu 2026	Harian
VT · VANGUARD INTERNATIONAL EQUITY INDEX…	0,00%	8.760 SH	8 Agu 2026	Harian
VTWV · VANGUARD SCOTTSDALE FUNDS	0,00%	3.882 SH	8 Agu 2026	Harian
VTHR · VANGUARD SCOTTSDALE FUNDS	0,00%	933 SH	8 Agu 2026	Harian
ESGV · VANGUARD WORLD FUND	0,00%	3.329 SH	8 Agu 2026	Harian

RNA Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

RNA Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

Rata-rata bergerak dan lapisan tumpang tindih

Volume

Osilator

Momentum dan tren

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Profitabilitas Margin kotor, operasional, dan bersih; ROE, ROA, ROIC

Kesehatan Keuangan Utang, likuiditas, solvabilitas — kekuatan neraca

Pertumbuhan Pertumbuhan Pendapatan, EPS, dan Laba Bersih: YoY, CAGR 3T, CAGR 5T

Metrik Per Saham EPS, nilai buku per saham, arus kas per saham, dividen per saham

Efisiensi Modal Perputaran aset, perputaran persediaan, perputaran piutang

RNA Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

Target Harga 12 Bulan

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor

Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas

Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir

Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap

Pemilik institusional (13F) 20 pengaju · $102.7M total · Per tanggal 30 Juni 2026

Orang dalam perusahaan 20 orang dalam · 11 pejabat · 9 direktur

Aktivis & pemilik 5%+ 1 saham

Kepemilikan ETF Dimiliki oleh 15 ETF